Ubs Group Ag Molecular Partners Ag Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Molecular Partners Ag stock. As of the latest transaction made, Ubs Group Ag holds 5,339 shares of MOLN stock, worth $22,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,339

Previous 10,199 47.65%

Holding current value

$22,530

Previous $38,000 47.37%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$3.47 - $4.22 $16,864 - $20,509	-4,860 Reduced 47.65%	5,339 $20,000
Q2 2025 Aug 14, 2025	BUY	$3.54 - $4.28 $13,621 - $16,469	3,848 Added 60.59%	10,199 $38,000
Q1 2025 May 13, 2025	SELL	$3.76 - $5.81 $1,958 - $3,027	-521 Reduced 7.58%	6,351 $24,000
Q4 2024 Feb 14, 2025	BUY	$4.58 - $6.78 $7,447 - $11,024	1,626 Added 31.0%	6,872 $32,000
Q3 2024 Nov 14, 2024	BUY	$4.62 - $8.58 $8,246 - $15,315	1,785 Added 51.57%	5,246 $26,000

Q2 2024 Aug 13, 2024	BUY	$3.32 - $11.01 $10,408 - $34,516	3,135 Added 961.66%	3,461 $25,000
Q1 2024 May 13, 2024	BUY	$3.73 - $5.0 $1,215 - $1,630	326 New	326 $1,000
Q4 2022 Feb 08, 2023	BUY	$6.03 - $7.08 $17,836 - $20,942	2,958 New	2,958 $19,000
Q2 2022 Aug 10, 2022	SELL	$5.98 - $21.8 $3,653 - $13,319	-611 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$16.51 - $31.89 $46,161 - $89,164	-2,796 Reduced 82.07%	611 $12,000
Q4 2021 Feb 14, 2022	BUY	$9.99 - $20.49 $34,035 - $69,809	3,407 New	3,407 $65,000
Q3 2021 Nov 15, 2021	SELL	$18.34 - $21.0 $421 - $483	-23 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$19.25 - $21.01 $442 - $483	23 New	23 $0

Others Institutions Holding MOLN

# of Institutions

Shares Held

3.58M

Call Options Held

Put Options Held

View Full List

About MOLECULAR PARTNERS AG

Ticker MOLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,514,000
Market Cap $137M
Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...

More about MOLN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account